演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

当院におけるXELIRI±ベバシズマブ療法の検討

演題番号 : P18-2

[筆頭演者]
演者)田中 健士郎:1 
[共同演者]
横山 裕之:1、大津 智尚:1、岸田 貴喜:1、小林 大悟:1、山中 雅也:1、間下 優子:1、野田 純代:1、杉本 博行:1、望月 能成:1、谷口 健次:1

1:小牧市民病院・外科

 

[Background] The efficacy and tolerability of XELIRI ± bevacizumab therapy for unresectable or recurrent colorectal cancer have been proved and already introduced in daily clinical practice. We retrospectively analyze the efficacy and safety of XELIRI ± bevacizumab therapy in our hospital and compare with previous reports. [Methods] Thirty-six patients with unresectable or recurrent colorectal cancer who underwent XELIRI ± bevacizumab therapy in our hospital from April 1, 2012 to February 28, 2018 were included (the median observation time was 13.8 months). Capecitabine: 1600 mg/m²/day, Irinotecan: 200 mg/m², Bevacizumab: 7.5 mg/kg as a standard amount. [Results] The median age was 65.5 years (34-78). male / female = 22/14, PS 0/1 = 32/4, KRAS wild/mutant = 17/19, UGT1A1 wild: 15, *6 hetero: 10, *28 hetero: 8, complex hetero: 2, *6 homo: 1, complex hetero and *6 homo receive irinotecan in half the amount. Bevacizumab was not received in two patients with thrombophilia and bleeding risk. Primary / Secondary / Third treatment line: 10/25/1. The median number of treatment courses = 8.5 courses (2-38). The efficacy was CR / PR / SD / PD = 1/7/21/7, the response rate was 22.2% and the disease control rate was 80.5%. The median progression free survival was 6.65 months (1.5-30.6) and the median overall survival was 13.8 months (2.6-54). For adverse events, the hematologic toxicity of Grade3 and above was 8.3% (3 cases) of leukopenia, 27.7% (10 cases) of neutropenia, 8.3% (3 cases) of FN. Although the incidence of neutropenia is larger than previous reports, we deal appropriately with postponement and weight loss. [Conclusion] The efficacy and tolerability of XELIRI ± bevacizumab therapy in our hospital is equivalent of previous reports.

キーワード

臓器別:大腸・小腸

手法別:化学療法

前へ戻る